Literature DB >> 20497147

Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease.

M Estep1, D Armistead, N Hossain, H Elarainy, Z Goodman, A Baranova, V Chandhoke, Z M Younossi.   

Abstract

BACKGROUND: Progression of non-alcoholic fatty liver disease (NAFLD) can be facilitated by soluble molecules secreted by visceral adipose tissue (VAT). MicroRNAs (miRNAs) are likely to regulate some of these molecular pathways involved in pathogenesis of NAFLD. AIM: To profile miRNA expression in the visceral adipose tissue of patients with NAFLD.
METHODS: Visceral adipose tissue samples were collected from NAFLD patients and frozen. Patients with biopsy-proven NAFLD were divided into non-alcoholic steatohepatitis (NASH) (n = 12) and non-NASH (n = 12) cohorts controlled for clinical and demographic characteristics. Extracted total RNA was profiled using TaqMan Human MicroRNA arrays. Univariate Mann-Whitney comparisons and multivariate regression analysis were performed to compare miRNA profiles.
RESULTS: A total of 113 miRNA differentially expressed between NASH patients and non-NASH patients (P < 0.05). Of these, seven remained significant after multiple test correction (hsa-miR-132, hsa-miR-150, hsa-miR-433, hsa-miR-28-3p, hsa-miR-511, hsa-miR-517a, hsa-miR-671). Predicted target genes for these miRNAs include insulin receptor pathway components (IGF1, IGFR13), cytokines (CCL3, IL6), ghrelin/obestatin gene, and inflammation-related genes (NFKB1, RELB, FAS). In addition, two miRNA species, hsa-miR-197 and hsa-miR-99, were significantly associated with pericellular fibrosis in NASH patients (P < 0.05). Levels of IL-6 in the serum negatively correlated with the expression levels of all seven miRNAs capable of down regulating IL-6 encoding gene.
CONCLUSIONS: miRNA expression from VAT may contribute to the pathogenesis of NAFLD - a finding which may distinguish relatively simple steatosis from NASH. This could help identify potential targets for pharmacological treatment regimens and candidate biomarkers for NASH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20497147     DOI: 10.1111/j.1365-2036.2010.04366.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  62 in total

1.  A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA.

Authors:  Sophie C Cazanave; Justin L Mott; Nafisa A Elmi; Steven F Bronk; Howard C Masuoka; Michael R Charlton; Gregory J Gores
Journal:  J Lipid Res       Date:  2011-06-01       Impact factor: 5.922

Review 2.  Micro RNAs in the development of non-alcoholic fatty liver disease.

Authors:  Glenn S Gerhard; Johanna K DiStefano
Journal:  World J Hepatol       Date:  2015-02-27

Review 3.  MicroRNAs and liver disease.

Authors:  Thomas A Kerr; Kevin M Korenblat; Nicholas O Davidson
Journal:  Transl Res       Date:  2011-02-02       Impact factor: 7.012

4.  High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis.

Authors:  Fatjon Leti; Ivana Malenica; Meera Doshi; Amanda Courtright; Kendall Van Keuren-Jensen; Christophe Legendre; Christopher D Still; Glenn S Gerhard; Johanna K DiStefano
Journal:  Transl Res       Date:  2015-05-04       Impact factor: 7.012

Review 5.  microRNAs: fad or future of liver disease.

Authors:  Ashley M Lakner; Herbert L Bonkovsky; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

6.  microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis.

Authors:  Timea Csak; Shashi Bala; Dora Lippai; Abishek Satishchandran; Donna Catalano; Karen Kodys; Gyongyi Szabo
Journal:  Liver Int       Date:  2014-07-28       Impact factor: 5.828

7.  Circulating microRNAs in patients with non-alcoholic fatty liver disease.

Authors:  Mehmet Celikbilek; Mevlut Baskol; Serpil Taheri; Kemal Deniz; Serkan Dogan; Gokmen Zararsiz; Sebnem Gursoy; Kadri Guven; Omer Ozbakır; Munis Dundar; Mehmet Yucesoy
Journal:  World J Hepatol       Date:  2014-08-27

8.  The effect of miRNA-122 in regulating fat deposition in a cell line model.

Authors:  Yu-Qiang Nie; Jie Cao; Yong-Jian Zhou; Xia Liang; Yan-Lei Du; Yu-Jui Yvonne Wan; Yu-Yuan Li
Journal:  J Cell Biochem       Date:  2014-05       Impact factor: 4.429

9.  KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.

Authors:  Yu-Shui Ma; Ting-Miao Wu; Bin Qian; Yu-Shan Liu; Hua Ding; Ming-Ming Fan; Ji-Bin Liu; Fei Yu; Hui-Min Wang; Yi Shi; Li-Peng Gu; Liu Li; Lin-Lin Tian; Pei-Yao Wang; Gao-Ren Wang; Zhi-Jun Wu; Qi-Fei Zou; Chang-Chun Ling; Da Fu
Journal:  J Cell Mol Med       Date:  2021-02-23       Impact factor: 5.310

10.  NOD2 expression is regulated by microRNAs in colonic epithelial HCT116 cells.

Authors:  Alice Y Chuang; Jim C Chuang; Zili Zhai; Feng Wu; John H Kwon
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.